Pharmacological studies with chemical inhibitors that inhibit ATX activity and LPA signaling in the liver of NAFLD animal models show an effect only on liver fibrosis and not on liver steatosis [241], although a genetic confirmation of this effect is still lacking. The gene discussed is ENPP2; the disease is Hepatic fibrosis.